Zynerba Receives Orphan Drug Designation For Cannabidiol To Treat 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. received orphan drug designation from the U.S. Food and Drug Administration (FDA) for cannabidiol (CBD) for use in treating 22q11.2 deletion syndrome (22q). 22q is a rare condition featuring physical abnormalities and debilitating neuropsychiatric and behavioral symptoms including anxiety, withdrawn behavior, and social interaction problems. The resulting drug therapy will be called Zygel CBD gel.

As the second most common chromosomal disorder after Down syndrome, 22q is caused by a small missing piece of the 22nd chromosome. It is considered a midline condition, with physical symptoms including characteristic palate abnormalities, heart defects, immune dysfunction, and . . .